Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeNeBio dose reduction study of IL-17/IL-23 biologics in psoriasis
NL-OMON29024Not yet recruiting
- Sponsor
- ZonMw
- Start
- Dec 2019
- Countries
- 1
01
Overview
Randomised, open-label trial in plaque psoriasis (2 arms), sponsored by ZonMw. Primary endpoint: Cumulative incidence of persistent flares. Planned start Dec 2019; status: not yet recruiting.
02
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON29024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29024.